X-linked (5 15 ) autosomal dominant (30 40 ) or autosomal recessive (50 60 ) The remaining patients represent isolated cases of -% -% -% which the inheritance trait can not be established . 1
To date, 20 autosomal dominant RP (adRP) genes have been reported ( ). One of the major genes http://www.sph.uth.tmc.edu/Retnet/ underlying this disorder is rhodopsin ( ) coding for the light absorbing molecule that initiates the signal transmission cascade in rod RHO photoreceptors. According to the literature, mutation prevalence ranges from 0 to 50 cases of adRP in cohorts from various RHO % geographical origins, with higher numbers reported in the United States .
-18
The genetic and phenotypic heterogeneity is not only found in RP in general but also specifically reflected in adRP with RHO mutations: Over 120 mutations have been identified in different sites of the gene including specific hot spots (   ,  ,  ) . http://www.sph.uth.tmc.edu/Retnet/ http://www.hgmd.cf.ac.uk/ac/all.php http://www.retina-international.org/sci-news/rhomut.htm 19 Certain mutations in lead to diffuse rod-cone dysfunction whereas other cases are implicated in a more restricted disease that RHO may predominate in the inferior part of the retina such as in sector RP . Phenotypic classifications have been proposed to reflect this 20 variability. In particular, Cideciyan and co-workers have distinguished two classes of disease expression with allele-specificity : class A 21 mutants show severely generalized abnormal rod function early in life with a constant rate of cone disease progression across the retina with time. Class B mutants show more restricted disease and absent or lateonset night blindness.
Other classifications have been proposed based on the underlying pathogenic mechanism involved in adRP due to mutations. RHO Mendes and co-workers classified the different types of mutations in 6 groups. Class I refers exclusively to rhodopsin mutations that fold correctly but are not transported to the outer segment. Class II, refers to mutations that misfold, are retained in the endopasmic reticulum (ER) and cannot easily reconstitute with 11--retinal. Class III refers to mutations that affect endocytosis. Class IV mutations do not cis affect folding but might affect rhodopsin stability and posttranslational modification. Similarly, Class V mutations have no obvious per se folding defect but show an increased activation rate for transducin. Mutants that appear to fold correctly but lead to the constitutive activation of opsin in the absence of the chromophore and in the dark constitute Class VI. Other mutations with unclear biochemical or cellular defect, or uninvestigated defect were not classified . 19
Our comprehensive study presented herein aim to investigate in detail a French adRP cohort coming from 2 different clinical centers, namely Quinze-Vingts hospital in Paris and the Centre Hospitalier R gional in Montpellier located in the south of France. We will present é the prevalence of rhodopsin mutations in this cohort and show precise phenotype-genotype correlations. Novel mutations will be analyzed on its predicted pathogenic mechanism as well as frequently mutated sites will be presented as putative candidates for therapeutic approaches.
METHODS Clinic
Seventy-nine families with a provisional diagnosis of autosomal dominant rod-cone dystrophy, (adRP) were ascertained in the CIC of the Quinze-Vingts hospital, Paris (67 families) and in Montpellier (12 families). Informed consent was obtained from each patient and normal individual controls after explanation of the study and its potential outcome. The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committees. Each patient underwent full ophthalmic examination with assessment of best corrected visual acuity using ETDRS chart, kinetic and static perimetry and colour vision using the desaturated 
Mutation analysis
Total genomic DNA was extracted from peripheral leucocytes in blood samples by standard salting out procedures or according to 24 manufacturer recommendation (Puregen Kit, Qiagen, Courtaboeuf, France). Subsequently, either genotyping or direct sequencing of RHO was performed. For genotyping 2 to 3 polymorphic microsatellite markers within or contiguous to known adRP genes (RHO, RDS, ) was used. Results were analysed with  PRPF31, RP1, PRPF8, IMPDH1, PRPF3, NRL, CA4, CRX, TOPORS, PAP1, 
RESULTS

Mutation analysis
Thirteen index patients of the investigated 79 French autosomal dominant RP patients revealed a mutation ( ). These RHO Table 1 mutations co-segregated with the phenotype when tested in family members available. Three index patients showed each a novel missense mutation, while ten index patients revealed previously described mutations in ( and ). RHO Table 1 Figure 2a Index patient 2296 from family RP827 revealed the earlier described c.998_999insAGGC insertion leading to a predicted frameshift mutation (p.Ser334GlyfsX20), which is assumed to change the open reading frame and elongates the altered protein ( ). Figure 1g ). Figure 1h 
Prevalence of different mutations in France RHO
Together our study on autosomal dominant RP patients from France showed that 16.5 revealed novel or known mutations.
%
RHO
Mutations locations revealed no specific hot spots since they involved all exons. However, three mutations occurred at least in two families indicating that the p.Asn15Ser, p.Arg135Trp and the p.Pro347Leu substitutions in are frequent causes of RP in this population. RHO
Phenotypic characteristics of patients with mutation RHO
Thirty affected subjects, between age 8 and 62, from the 13 families found with mutation underwent complete clinical RHO examination. Their phenotypic details are summarized in . The group of patients reported here shows 3 distinct phenotypes and Table 2 resemble either class A or B mutants from the classification proposed by Cideciyan and co-workers : 21 observed in patients carrying mutations (p.Leu88Pro, p.Leu131Pro, p.Arg135Trp, a generalized rod-cone dysfunction p.Ser334GlyfsX20, p.Gln344Pro, p.Pro347Leu), which resemble the class A mutants.
associated with the p. Asn15Ser mutation and a sector RP associated with the p.Met207Lys substitution. Due to the a restricted chorioretinal dystrophy predominant at the posterior pole more restricted phenotype, we classified the two latter mutations as class B mutations. . There was no correlation between OCT abormalities and genotype. Cystoid Macular Edema (CME) is present in Table 2 4/30 patients in association with 4 different genotypes. A perifoveal ring of hyper-autofluorescence is present 13/18 patients for whom fundus autofluorescence imaging has been performed. Absence of this ring is associated with irregular loss of autofluorescence within the macula in relation with atrophic changes ( ). ERG responses are usually undetectable for both scotopic and photopic recordings Figure 3 after 30 or show only residual photopic Flicker responses. When ERGs are detectable, in younger patients, they usually show more decreased amplitudes for scotopic than photopic responses with implicit time shift, consistent with generalized rod-cone dysfunction.
was seen in 2 families (PB41 and PB42) carrying the same p.Asn15Ser change. Five patients, from age 28 to 60, underwent Sector RP full ophthalmic examination. Night blindness is an inconstant sign in these subjects who all retain a normal central vision with inferior peripheral field defect correlated with fundus abnormalities. ERG responses show decreased scotopic responses with additional photopic abnormalities in some patients. There is however no implicit time shift consistent with a restricted rod-cone dysfunction.
One additional family, F475 with a novel p.Met207Arg, shows also restricted chorioretinal degeneration. Phenotype-genotype correlations are described in more details elsewhere (Audo et al., 2010, ). Briefly, onset of symptoms appears in the fourth decade in press in this family with moderate night blindness and asymmetric visual loss. Affected family members show patchy areas of chorioretinal atrophy within the posterior pole ( ) with decreased ERG response amplitudes for both scotopic and photopic responses and no Figure 3 implicit time shift consistent with restricted disease.
DISCUSSION
The current study reports mutation spectrum on the rhodopsin gene in a cohort of patients from 2 major French centres and further outlines phenotypic variability associated with rhodopsin mutation showing both, generalized or sectorial retinal degeneration. To the best of our knowledge to date only two studies on mutations in a French cohort were published: One describing the prevalence of RHO RHO mutations in Southern France and the other reported on the identification of 5 new mutations with no information on prevalence and ethnic origin , . 13 26 The overall prevalence of mutations in our cohort is 16.5 . This is consistent with previous reports on European cohorts RHO % including Spain (20 ) , Germany (16 ) , Italy (16 ) and Southern France (10 ). This is higher than reports from China (2 7 )
, Japan (0 6 ) India (0 2 ) and South-Africa (7 ) . Studies from the UK and Norway revealed higher numbers 14 15 27 -% 16 -% 17 % 18 with 30 50 , , . However, the studied cohorts were small (12 20 families) and thus these results must be validated in larger -% 8 9 28 -cohorts. In the US population mutations were shown to account for up to 30 of adRP . The prevalence of the p.Pro23His RHO % 3 -7 mutation in the US has been reported as high as 12 of adRP due to a founder effect from a common British ancestor . This mutation
has never been found in European cohorts of adRP , including the current report, nor in Asian cohorts , , which would account for 30 31 32 differences in the overall mutation prevalence between the American population and reports from other populations. RHO Three novel changes were identified in the current study: p.Leu88Pro, p.Met207Lys and Gln344Pro. Previously a c.1030C>T change leading to a p.Gln344Stop was associated with normal phototransduction function but with mislocalization . Furthermore, Tai and co-workers identified the direct interaction between a dynein light-chain subunit and the 34 C-terminus of rhodopsin, which is important for the correct protein transport of post-Golgi rhodopsin-containing vesicles along the microtubules up to the outer segment . Different C-terminal mutations were unable to interact with this domain and thus led to a 35 trafficking defect. A similar mechanism can be advocated for the novel reported change p.Gln344Pro.
The 10 other families identified with mutation showed already described changes. The p.Asn15Ser mutation was identified in RHO two different families from a similar region of France and thus represents probably a founder effect. Asn15 represent one of the important N-glycosylation sites of RHO. Thus the underlying pathogenic mechanism of the p.Asn15Ser was proposed to be trafficking defect . 36
The p.Leu131Pro mutation was identified in a large family from Martinique with typical diffuse rod-cone dystrophy, type A from Cideciyan and co-workers . This amino-acid substitution is assumed to lead to misfolding . Since this exchange has also been 21 37 previously reported in another study from France , it may represent a major mutation in the affected French population. 26
The p.Arg135Trp was found in two unrelated families and was associated with typical severe diffuse rod-cone dystrophy, type A from Cideciyan and co-workers as previously reported . Of notes, none of the examined patients in these 2 families demonstrated the 21 38 39 white dots previously described in association with this genotype , . An explanation would be that the examined patients were either 39 40 too young or too old to exhibit this distinct feature since, Oh and co-worker have reported the transient nature of these white dots appearing in the second decades of life then fading to leave place to RPE atrophy and bone spicules. It is also noteworthy that these white dots, which are located at the level of the RPE, are not specific of the p.Arg135Trp mutation since it was also seen in association with other mutations in our series and may represent a non-specific sign of photoreceptor degeneration (see on clinical data). RHO table 2 The p.Pro347Leu mutation was the most prevalent, found in 4 families which would represent 5 of our adRP families. This mutation % has also been reported in other populations , , , , . Although the 4 families studied herein were unrelated and from different 8 10 29 32 41 geographical origin, a founder effect cannot be excluded. Haplotype analysis was not performed for this study. However, the gene location is a known hotspot through a higher probability of C>T transition due to a CpG sequence and 6 disease causing amino-acid substitutions 3 have reported at this location (see ). Again, it was suggested that for these http://www.retina-international.org/sci-news/rhomut.htm substitutions a trafficking defect represent the pathogenic mechanism. Patients carrying the p.Pro347Leu mutation have a comparable phenotype as patients carrying the p.Gln344Pro and p.Ser334GlnfsX20 changes, all being located at the C-terminus, with early onset-night blindness, and generalized severe rod-cone dystrophy with loss of central vision in the 5 decades. The severity of the disease associated th with C-terminal changes within the cytoplasmic domain is well documented in the literature showing a worse prognosis compared 42 -44 in particular to the p.Pro23His mutation located in the N-terminal intradiscal/extracellular portion of the protein , . Our cohort in 43 44 whom genotype-phenotype correlation was performed is still too small to judge the severity associated with a specific mutation but recurrent follow-up will further address this question.
One additional criterion that will need to be further precisely evaluated is the course of macular involvement: perifoveal and foveal atrophy is not uncommon in our series (see with clinical details) as well as cystoid macular edema which was present in 4/31  table 2 patients with no genotype-specificity. These macular changes are responsible for decreased central vision and their prevention should be the major target of future therapeutic interventions.
Further longitudinal studies will precise the course of the disease for each genotype and will help identifying suitable markers and therapeutic windows for photoreceptor rescue, gene replacement or cell based therapies.
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c.1040C>T p.Pro347Leu 29 Motion; CME: Cystoid Macular Edema; * ERG performed with skin electrodes which precluded us to have a precise quantification of abnormalities, AF: autofluoresce., OCT: Optical Coherence Tomography.
